Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China flag China · Delayed Price · Currency is CNY
25.56
-0.03 (-0.12%)
Feb 3, 2026, 9:55 AM CST

SHA:600566 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
6,1237,9979,6388,9767,6186,151
Other Revenue
20.3820.3816.5119.871314.25
6,1448,0179,6558,9967,6316,165
Revenue Growth (YoY)
-31.15%-16.96%7.32%17.90%23.77%-11.17%
Cost of Revenue
1,3951,6661,7841,5371,2771,130
Gross Profit
4,7496,3507,8717,4596,3545,035
Selling, General & Admin
2,5583,3874,3794,4774,0313,300
Research & Development
419.77444.78464.4553.3523.44243.75
Other Operating Expenses
108.31115.38146.24138.81120.999.9
Operating Expenses
3,0933,9254,9875,2054,6833,650
Operating Income
1,6562,4262,8842,2541,6711,385
Interest Expense
-13.94-27.27-17.58-30.41-34.9-33.03
Interest & Investment Income
314.46352.77357.81183.21171.4283.03
Other Non Operating Income (Expenses)
-109.43-1.03-0.83-1.2-0.41-0.58
EBT Excluding Unusual Items
1,8472,7503,2232,4051,8071,435
Gain (Loss) on Sale of Investments
30.2199.214.6-7.32114.5520.94
Gain (Loss) on Sale of Assets
0.090.20.135.220.653.35
Asset Writedown
-1.42-0.28-1.09-0.53-0.42-0.77
Other Unusual Items
128.98128.9860.42105.0928.9625.37
Pretax Income
2,0052,9783,2972,5081,9501,484
Income Tax Expense
351.68441.54470.03336.2233.22206.29
Earnings From Continuing Operations
1,6532,5372,8272,1721,7171,277
Minority Interest in Earnings
-2.29-5.15-4.28-0.971.96-
Net Income
1,6512,5322,8232,1711,7191,277
Net Income to Common
1,6512,5322,8232,1711,7191,277
Net Income Growth
-40.64%-10.32%30.04%26.27%34.60%-21.30%
Shares Outstanding (Basic)
919917916890886835
Shares Outstanding (Diluted)
919917916908900835
Shares Change (YoY)
-0.05%0.08%0.91%0.91%7.82%2.36%
EPS (Basic)
1.802.763.082.441.941.53
EPS (Diluted)
1.802.763.082.391.911.53
EPS Growth
-40.61%-10.39%28.87%25.13%24.84%-23.12%
Free Cash Flow
1,0382,0023,1622,3771,6461,352
Free Cash Flow Per Share
1.132.183.452.621.831.62
Dividend Per Share
2.0902.0901.3000.8800.6800.450
Dividend Growth
60.77%60.77%47.73%29.41%51.11%-63.41%
Gross Margin
77.30%79.21%81.52%82.91%83.27%81.67%
Operating Margin
26.96%30.26%29.87%25.05%21.89%22.47%
Profit Margin
26.88%31.58%29.24%24.13%22.53%20.72%
Free Cash Flow Margin
16.90%24.97%32.76%26.42%21.57%21.93%
EBITDA
1,9572,7273,1852,5611,9641,666
EBITDA Margin
31.86%34.01%32.99%28.47%25.74%27.03%
D&A For EBITDA
301301.08301.2307.14293.13280.95
EBIT
1,6562,4262,8842,2541,6711,385
EBIT Margin
26.96%30.26%29.87%25.05%21.89%22.47%
Effective Tax Rate
17.54%14.83%14.26%13.41%11.96%13.91%
Revenue as Reported
6,1448,0179,6558,9967,6316,165
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.